AGP Executive Report
Last update: 7 hours agoCancer Care & Trials: Real-world data from the 2026 Kidney Cancer Research Summit suggests TKI-based regimens may deliver better disease control and durability in metastatic translocation RCC than non-TKI approaches. Rare Kidney Disease Pipeline: Akebia dosed the first patient in a Phase 2 basket trial of ebribafusp for complement-mediated kidney disorders, with initial results expected in 2027. Autoimmune Innovation: Evaxion says it has begun applying its AI-Immunology™ platform to autoimmune diseases, with experimental updates planned for PEGS Europe in November. Policy & Access: Kentucky is pushing to loosen state rules that block a new federal GLP-1 access program for Medicaid patients. Public Health & Safety: Russia tightened border Ebola screening, hospitalizing arrivals with symptoms. Health Systems & Costs: Opinion pieces highlight how insurance design can keep patients powerless, and another story warns that where you get an MRI can sharply change Medicare out-of-pocket costs. Mental Health: Coverage also points to the mental-health toll of working remotely in isolation and spotlights community efforts to support men’s suicide prevention. Healthcare Governance: SA Health reprimanded an employee for inappropriately accessing Tony Modra’s medical records.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.